絞り込み

17713

広告

伊方原発3号機 定期検査 約半年ぶりに再開 トラブル相次ぎ中断 (NHK)

トラブルが相次いだことをうけて中断していた、愛媛県伊方町にある伊方原発3号機の定期検査について、四国電力は5日、およそ半年ぶりに再開しました。 伊方原発3号機は...

  1. 形成まもない銀河を現在の宇宙の中で発見 ...
  2. [医学] 間もなく増えるであろう小児の急...
  3. 台所のみ、売り上げ月500万円 レストラ...
  4. 埼玉県もTikTok利用停止 知事「情報...

ニュース一覧

New drugs in melanoma: It's a whole new world.

著者 Eggermont AM , Robert C
Eur J Cancer.2011 Jul 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France.

スターを付ける スターを付ける     (86view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

Research Materials

Current developments in systemic therapies for melanoma are spectacular. Over the last 40years no one drug or combination of drugs demonstrated any impact on survival in metastatic melanoma. In contrast, in 2011 a number of new drugs will be approved. In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand CTLA-4, has been approved for patients with advanced melanoma in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA). Also in 2011, a significant survival benefit of the combination of ipilimumab with dacarbazine compared with dacarbazine alone for first-line treatment was reported. Other monoclonal antibodies targeting T-cell ligands, such as programmed death-1 (PD-1), also show promise. Various inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) yield high response rates in patients harbouring the BRAF-V600E mutation. A significant impact on both progression-free and overall survival was demonstrated for vemurafenib compared with dacarbazine in a phase-III trial. Approval is expected in 2011. Both drugs had only modest effects of 2-3months on median survival, so combination therapies must be explored. BRAF inhibitors in combination with mitogen-activated protein kinase (MEK) inhibitors show great potential. Moreover, combinations of immunomodulators and pathway inhibitors are expected to be very active, and phase-III trials are planned. Pegylated interferon-α2b was approved in 2011 on the basis of the results of the European Organisation for Research and Treatment of Cancer (EORTC) 18991 phase-III trial demonstrating a sustained impact on relapse-free survival in patients with lymph-node-positive melanoma. The efficacy of adjuvant therapy with ipilimumab is assessed in the now fully accrued EORTC18071 trial. Adjuvant trials with BRAF and MEK inhibitors are in the planning phase. Never was there a more exciting period in the world of melanoma treatment.
PMID: 21802280 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード